Sales of migraine drug exceed expectations at Lundbeck during third quarter
![Photo: Thomas Borberg](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13447092.ece/ALTERNATES/schema-16_9/doc7ic1uuqrgdyen0db6c0.jpg)
There were no surprises in Lundbeck's Q3 report released on Wednesday morning. The company has more or less performed as it expected to – exceeding some targets, meeting some exactly, and narrowly missing others.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Lundbeck ready to take Genmab antibody to phase II
For subscribers